GTBP GT Biopharma Inc

GT Biopharma, Inc. engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1615, OXS-3550, OXS-3550, PainBrake, GTP-004, and GTP-011. The company was founded in 1965 and is headquartered in Beverly Hills, CA.

$14.25  -1.01 (-6.62%)
As of 06/24/2021 15:59:49 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/31/1969
Outstanding shares:  21,127,718
Average volume:  382,049
Market cap:   $326,211,966
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   13.33
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy